Bone densitometry vendor Norland Medical Systems and its partner, U.K.-based McCue, have received premarket approval clearance from the Food and Drug Administration for CubaClinical, an ultrasound bone measurement system. CubaClinical is a dry system and
Bone densitometry vendor Norland Medical Systems and its partner, U.K.-based McCue, have received premarket approval clearance from the Food and Drug Administration for CubaClinical, an ultrasound bone measurement system. CubaClinical is a dry system and carries a large clinical database, according to Norland executives.
After terminating a two-year alliance with Canadian firm IMRO, White Plains, NY-based Norland signed an exclusive distribution and service agreement in June 1999 with McCue, which developed CubaClinical (SCAN 8/4/99). Norland distributes McCue systems in the U.S., Canada, Europe, Africa, the Middle East, and the Pacific Rim. CubaClinical lists at approximately $20,000.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.